Understanding the Uptake of Nanomedicines at Different Stages of Brain Cancer Using a Modular Nanocarrier Platform and Precision Bispecific Antibodies
Zachary H. Houston, Jens Bunt, Kok‐Siong Chen, Simon Puttick, Christopher B. Howard, Nicholas L. Fletcher, Adrian V. Fuchs, Jiwei Cui, Yi Ju, Gary Cowin, Xin Song, Andy Boyd, Stephen M. Mahler, Linda J. Richards, Frank Caruso, Kristofer J. Thurecht
Abstract
. This was evaluated by establishing brain tumors using a spontaneous and endogenously derived glioblastoma model providing a unique opportunity to assess these parameters individually and compare the results across multiple mice. We also quantitatively demonstrate that smaller nanomedicines (20 nm) can indeed cross the BBB and accumulate in tumors at earlier stages of the disease than larger analogues, therefore opening the possibility of developing patient-specific nanoparticle treatment interventions in earlier stages of the disease. Importantly, these results provide a more predictive approach for designing efficacious personalized nanomedicines based on a particular patient's condition.